BG
TEVA icon

BlackRock Group’s Teva Pharmaceuticals TEVA Stock Holding History

BlackRock Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$111M Buy
3,075,439
+178,716
+6% +$7.14M 0.05% 395
2016
Q3 		$133M Sell
2,896,723
-721,705
-20% -$37.7M 0.07% 339
2016
Q2 		$182M Buy
3,618,428
+176,534
+5% +$9.4M 0.09% 260
2016
Q1 		$184M Sell
3,441,894
-734,241
-18% -$43.1M 0.1% 243
2015
Q4 		$274M Buy
4,176,135
+137,154
+3% +$8.48M 0.15% 153
2015
Q3 		$228M Sell
4,038,981
-366,853
-8% -$23.8M 0.13% 179
2015
Q2 		$260M Buy
4,405,834
+233,831
+6% +$14.4M 0.14% 173
2015
Q1 		$260M Buy
4,172,003
+418,458
+11% +$24.3M 0.14% 174
2014
Q4 		$216M Buy
3,753,545
+977,837
+35% +$54.5M 0.12% 201
2014
Q3 		$149M Buy
2,775,708
+590,214
+27% +$31.3M 0.09% 266
2014
Q2 		$115M Buy
2,185,494
+361,387
+20% +$18.5M 0.07% 341
2014
Q1 		$96.4M Buy
1,824,107
+1,559,507
+589% +$72.1M 0.06% 366
2013
Q4 		$10.6M Sell
264,600
-233,800
-47% -$9.21M 0.01% 904
2013
Q3 		$18.8M Buy
498,400
+272,600
+121% +$10.6M 0.01% 776
2013
Q2 		$8.85M Buy
+225,800
New +$8.79M 0.01% 889

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

BlackRock Group's TEVA Position: Q4 2016 in Review

BlackRock Group increased its Teva Pharmaceuticals (TEVA) stake by 6.2% in Q4 2016, buying an estimated $7.14M and bringing the position to 3,075,439 shares worth $111M. The position accounts for 0.05% of the portfolio, ranked #395.

BlackRock Group first reported a position in TEVA in Q2 2013 and has held it in 15 quarters since. The position peaked at $274M in Q4 2015. 739 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • BlackRock Group held 3,075,439 shares of Teva Pharmaceuticals worth $111M as of Q4 2016.
  • BlackRock Group bought 178,716 Teva Pharmaceuticals shares in Q4 2016, an estimated $7.14M.
  • Teva Pharmaceuticals made up 0.05% of BlackRock Group's portfolio in Q4 2016, its #395 holding.
  • BlackRock Group first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Teva Pharmaceuticals position peaked at $274M in Q4 2015.
  • 739 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.